---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-22-000046"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:59:05.868648+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prothena Q3 2022 net loss $45.8M vs income $109.2M y/y; cash $497M; cuts FY22 net cash burn guidance to $108-120M

## Summary
- Net loss $45.8M ($0.97 per share) vs net income $109.2M ($2.13 diluted EPS) in Q3 2021.
- Total revenue $1.5M vs $139.2M y/y, primarily due to prior year BMS and Novo Nordisk milestones.
- Cash and restricted cash $497.0M; no debt; shares outstanding ~48.4M as of Oct 26.
- Updated FY2022 net cash burn guidance $108-120M (down from $120-132M); year-end cash ~$522M.
- R&D expenses $39.9M in Q3 2022 vs $18.0M y/y, driven by manufacturing and clinical costs.

## SEC filing metadata
- accession: 0001559053-22-000046
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/0001559053-22-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/prta-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-22-000046
- JSON: https://secwatch.observer/filing/0001559053-22-000046.json
- Plain text: https://secwatch.observer/filing/0001559053-22-000046.txt

## Key facts
- Earnings Releases
  PROTHENA CORP PUBLIC LTD CO reported third quarter ended September 30, 2022 results: revenue $1.5 million, net income net loss of $45.8 million, EPS $0.97.
  - Period: third quarter ended September 30, 2022
  - Revenue: $1.5 million
  - Net income: net loss of $45.8 million
  - EPS: $0.97
  - Result: reported results
  source text: For the third quarter and first nine months of 2022, Prothena reported a net loss of $45.8 million and $123.3 million, respectively, as compared to a net income o f $109.2 million and $100.2 million for the third quarter and first nine months of 2021, respectively. Net loss per share for the third quarter of 2022 and first nine months of 2022 was $0.97, and $2.63, respectively, a s compared to net income per share on a diluted basis of $2.13 and $2.12 f or the third quarter and first nine months of 2021, respectively. Prothena reported total revenue of $1.5 million and $4.0 million for the third quarter and first nine months of 2022, respectively, primarily from collaboration revenue from BMS.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/0001559053-22-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.